NDASUBCUTANEOUSSOLUTION
Approved
Apr 2008
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
11
Data completeness
5/8 — Partial
RELISTOR (methylnaltrexone bromide) by Bausch Health is mu-opioid receptor. Approved for opioid-induced constipation, constipation. First approved in 2008.
Drug data last refreshed 20h ago
Mechanism of Action
mu-opioid receptor. As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted. This allows methylnaltrexone to function as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the…
Indications (2)
Worked on RELISTOR at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.